New class action for Endava plc (DAVA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/30/2026
The case alleges Millrose and certain of its top executives made false and/or misleading statement to investors.
Gas and diesel prices will soon drop rapidly thanks to President Donald J. Trump’s bold actions to unleash American Energy. On day one, the Trump Administration began dismantling the failed Biden-era anti-energy policies, cutting red tape, and ending the Democrats’ Green New Scam agenda. Today, under President Trump’s leadership, America is producing record amounts of […] The post President Trump Secures Major Deals to Unleash American Energy and Cut Gas Prices at the Pump appeared first on The White House.
SAN DIEGO, Oct. 25, 2026 -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Gildan Activewear Inc. (NYSE: GIL) publicly traded securities between February 19, 2025 and June 15, 2026, both dates inclusive (the "Class Period"), have...
Recently, the “Culture and Technology Roundtable” of the Macao International Forum was held at Macau University of Science and Technology. -- Recently, the “Culture and Technology Roundtable” of the Macao International Forum was held at Macau University of Science and Technology. The conference was jointly organized by the Macao Foundation, Chinese Cultural Figures Magazine, and Macau University of Science and Techno
Are you a former Anywhere Real Estate Inc. shareholder who exchanged your shares of Anywhere stock for Compass, Inc. common stock in connection with the January 2026 merger?
-- As Halloween approaches, AVIDLOVE is highlighting versatile fashion pieces that inspire creative seasonal styling. Guided by its brand philosophy, “Confidence is Your Stage,” the brand celebrates personal expression through contemporary designs, comfortable materials, and adaptable wardrobe options. From themed celebrations to everyday outfits, AVIDLOVE encourages fashion enthusiasts to explore new combinations an
-- Meshy is making AI-powered 3D content creation more accessible through a browser-based platform that supports text-to-3D and image-to-3D generation, AI texturing, auto-rigging, and developer API access. The platform also offers a free tier and browser-based utilities designed to help creators generate, inspect, and prepare 3D assets for applications including game development, design, and 3D printing. Meshy Brings
-- Developing effective school leaders requires more than preparing educators for administrative responsibilities. It also involves building their capacity to support teachers, navigate organizational challenges, make informed decisions, and create school environments where students can thrive. Dr. Anna Nolin, Superintendent of Newton Public Schools, brings decades of experience in educational leadership, mentoring,
Turkey-based garment producer outlines its denim production capacity, development services and manufacturing practices for brands seeking private-label and OEM partners. -- KASTAMONU, Turkey – October 22, 2026 – Urgan Textile is highlighting its manufacturing operations and product development services for international fashion brands. Founded in 1995, the company maintains its headquarters in Istanbul and operates a
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline
BEERSE, BELGIUM, Oct. 25, 2026 -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).1 These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development programme for subcutaneous amivantamab for patients with head and neck cancer.